<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6843332/results/search/disease/results.xml">
  <result pre="a member of the herpesviridae family. Herpesviruses establish life-long latent" exact="infections" post="within neurons, which may reactivate into lytic infections due"/>
  <result pre="life-long latent infections within neurons, which may reactivate into lytic" exact="infections" post="due to stress or immune suppression. There are nine"/>
  <result pre="There are nine human herpesviruses (HHV) posing health concerns from" exact="benign" post="conditions to life threatening encephalitis, including cancers associated with"/>
  <result pre="benign conditions to life threatening encephalitis, including cancers associated with" exact="viral" post="infections. The current treatment options for most HHV conditions"/>
  <result pre="HHV conditions mainly include several nucleoside and nucleotide analogs targeting" exact="viral" post="DNA polymerase. Although these drugs help manage infections, their"/>
  <result pre="issue. We analyzed the conservation rates of all proteins in" exact="herpes" post="simplex virus 1 (HHV-1), a representative of the HHV"/>
  <result pre="among all HHV-1 gene products, the virus will have a" exact="lower" post="chance of developing resistance to small molecules targeting pUL15."/>
  <result pre="of drugs to treat a wide range of HHVs. herpesviruses" exact="herpes" post="simplex virus 1 HHV-1 DNA packaging terminase pUL15 DNA"/>
  <result pre="of the world population are infected with a form of" exact="herpes" post="viruses [1]. Herpes viruses remain for the life of"/>
  <result pre="undetected and unaffected by antiviral drugs [2,3]. There are nine" exact="herpes" post="viruses that infect humans and their effects can range"/>
  <result pre="the lips and genitals, respectively, whereas HHV-6 and HHV-7 cause" exact="Roseola" post="in infants [5]. Human cytomegalovirus (CMV or HHV-5) is"/>
  <result pre="lethal diseases involving the lungs, gastrointestinal tract, liver, retina, and" exact="central nervous system" post="in immune compromised individuals, and is the leading cause"/>
  <result pre="immune compromised individuals, and is the leading cause of post-transplant" exact="infection" post="[6,7]. Congenital CMV results in an estimated 8000 cases"/>
  <result pre="individuals, and is the leading cause of post-transplant infection [6,7]." exact="Congenital" post="CMV results in an estimated 8000 cases of permanent"/>
  <result pre="year, affecting over 90% of infants who survive the initial" exact="infection" post="[8,9,10]. Chicken pox and shingles, caused by varicella-zoster virus"/>
  <result pre="over 90% of infants who survive the initial infection [8,9,10]." exact="Chicken pox" post="and shingles, caused by varicella-zoster virus (VZV), are manageable"/>
  <result pre="disease, and has been detected in approximately 70% of advance" exact="breast cancer" post="tumors [12,13]. Kaposi’s sarcoma-associated herpesvirus (KSHV) can result in"/>
  <result pre="and has been detected in approximately 70% of advance breast" exact="cancer" post="tumors [12,13]. Kaposi’s sarcoma-associated herpesvirus (KSHV) can result in"/>
  <result pre="in HIV-1 patients [14,15]. The pervasiveness and deleterious effects of" exact="herpes" post="viruses provides incentive for new approaches to antiviral drugs."/>
  <result pre="consists of two unique regions, unique long (UL) and unique" exact="short" post="(US), flanked by terminal inverted repeats [19]. The UL"/>
  <result pre="unique long (UL) and unique short (US), flanked by terminal" exact="inverted" post="repeats [19]. The UL sequence contains 107,943 residues and"/>
  <result pre="resistance, virulence, and pathogenesis. The most common antiviral strategy against" exact="herpes" post="viruses is based on nucleoside analogs targeting the viral"/>
  <result pre="against herpes viruses is based on nucleoside analogs targeting the" exact="viral" post="DNA polymerase and thymidine kinase. While these drugs are"/>
  <result pre="and CMV, respectively [22,23,24]. These compounds target HHV-1 pUL30, the" exact="viral" post="DNA polymerase, and HHV-1 pUL23, the viral thymidine kinase."/>
  <result pre="HHV-1 pUL30, the viral DNA polymerase, and HHV-1 pUL23, the" exact="viral" post="thymidine kinase. Regarding CMV, mutations in the viral kinase"/>
  <result pre="pUL23, the viral thymidine kinase. Regarding CMV, mutations in the" exact="viral" post="kinase pUL97 and polymerase pUL54 mediate resistance to ganciclovir"/>
  <result pre="adverse side effects of nucleoside analogs, new targets to treat" exact="herpes" post="viruses are being perused. The viral DNA packaging motor,"/>
  <result pre="new targets to treat herpes viruses are being perused. The" exact="viral" post="DNA packaging motor, namely its large terminase subunit, has"/>
  <result pre="large terminase subunit, has become a promising target for potential" exact="herpes" post="antivirals [29]. The HHV-1 terminase is composed of three"/>
  <result pre="several important roles in the packaging process, including identifying the" exact="viral" post="concatemeric DNA, as well as endonuclease and ATPase activity."/>
  <result pre="be interrupted, provided a feasible drug binding site. Inhibiting the" exact="viral" post="terminase or other components of the viral DNA packaging"/>
  <result pre="site. Inhibiting the viral terminase or other components of the" exact="viral" post="DNA packaging motor is expected to be more effective"/>
  <result pre="to be filled with the appropriate DNA for a viable" exact="viral" post="particle to be formed. Replication of the HHV genome"/>
  <result pre="their effectiveness in cell culture [36,37]. To develop more biologically" exact="stable" post="compounds, analogs have been derived from BDCRB, including acetylated,"/>
  <result pre="minimal [39]. Raltegravir, an HIV integrase inhibitor, exhibits efficiency against" exact="herpes" post="viruses. The effect of raltegravir on herpes viruses is"/>
  <result pre="exhibits efficiency against herpes viruses. The effect of raltegravir on" exact="herpes" post="viruses is attributed to an inhibition of the large"/>
  <result pre="attributed to an inhibition of the large subunit of the" exact="viral" post="terminase because it has the same RNase H-like fold"/>
  <result pre="the treatment of CMV. Letermovir is believed to inhibit the" exact="viral" post="terminase complex by targeting pUL56 because L241P, R369S, and"/>
  <result pre="evolution across different genes, the inferred rate multipliers from the" exact="posterior" post="distribution were plotted using Tracer version 1.6 [53]. 2.2."/>
  <result pre="2.2. Phylogenetic Tree Twenty-one HHV-1 UL15 gene homologs from various" exact="herpes" post="virus species were collected by BLAST [54] with HHV-1"/>
  <result pre="sequences were obtained from the Reference Sequence (RefSeq) database [55]." exact="Multiple" post="sequence alignment was performed with MUSCLE [56]. The ProtTest"/>
  <result pre="reverse placement of HHV-4 and BHV-6. Both the bootstrap and" exact="posterior" post="probabilities values are displayed on the Bayesian tree [61]."/>
  <result pre="probabilities values are displayed on the Bayesian tree [61]. 2.3." exact="Protein" post="Structure Modeling The amino acid sequence of HHV-1 pUL15"/>
  <result pre="obtained from the RefSeq database [55] (GeneID: 2703385). Only a" exact="partial" post="crystal structure of the C-terminus of pUL15 (PDB-ID: 4iox)"/>
  <result pre="C-terminus of pUL15 (PDB-ID: 4iox) [62] is available in the" exact="Protein" post="Data Bank (PDB) [63]. DNA packaging protein gp17 from"/>
  <result pre="as in vitro and in vivo techniques are traditionally the" exact="primary" post="methods for approaching virology research. Even so, the rapid"/>
  <result pre="accurate predictions to facilitate in vitro and in vivo studies." exact="Essential" post="information for better understanding viruses, including viral structures, interactions,"/>
  <result pre="in vivo studies. Essential information for better understanding viruses, including" exact="viral" post="structures, interactions, and evolution, which can be used to"/>
  <result pre="numerous diseases including roseola, post-transplant infections, neurological disabilities in infants," exact="chicken pox," post="shingles, lymphoma, nasopharyngeal carcinoma, Hodgkin’s disease, and infectious blisters"/>
  <result pre="infants, chicken pox, shingles, lymphoma, nasopharyngeal carcinoma, Hodgkin’s disease, and" exact="infectious" post="blisters on the lips and genitals. HHV-1 and HHV-2"/>
  <result pre="lips and genitals. HHV-1 and HHV-2 alone can result in" exact="neonatal infection," post="keratitis meningitis, encephalitis, and HHV-2 increases the likelihood of"/>
  <result pre="genitals. HHV-1 and HHV-2 alone can result in neonatal infection," exact="keratitis" post="meningitis, encephalitis, and HHV-2 increases the likelihood of HIV"/>
  <result pre="infection, keratitis meningitis, encephalitis, and HHV-2 increases the likelihood of" exact="HIV infection" post="by three-fold [83]. The ability of HHV to establish"/>
  <result pre="keratitis meningitis, encephalitis, and HHV-2 increases the likelihood of HIV" exact="infection" post="by three-fold [83]. The ability of HHV to establish"/>
  <result pre="it should have similarities to its counterparts in other human" exact="herpes" post="viruses. The phylogenetic analysis shows the level of similarity"/>
  <result pre="the level of similarity amongst HHV-1 UL15 and its human" exact="herpes" post="virus homologs within the context of the phylogenetic tree"/>
  <result pre="regions. HHV-1 also is closely related to the other human" exact="herpes" post="viruses, as well as those herpes viruses affecting high-value"/>
  <result pre="to the other human herpes viruses, as well as those" exact="herpes" post="viruses affecting high-value domesticated animals in the agriculture industry."/>
  <result pre="relationship between UL15 homologs of HHV-1 and the other human" exact="herpes" post="virus protein sequences is evident by the fact that"/>
  <result pre="viruses form a monophyletic clade in the tree. However, the" exact="short" post="branch lengths of the tree indicate that, overall, there"/>
  <result pre="of pUL15 To create a full-length model of pUL15, a" exact="partial" post="crystal structure of the C-terminal domain of pUL15 was"/>
  <result pre="indicate a more successful alignment because 2o0j is actually a" exact="partial" post="structure of 3cpe. The differences that are evident in"/>
  <result pre="pockets of g17 and pUL15 is only 0.27 indicating a" exact="limited" post="binding residue conservation. To determine how the binding energy"/>
  <result pre="the modeled pUL15-ATP complex is −255.13, which corresponds to the" exact="upper" post="range of the third quartile of the distribution of"/>
  <result pre="into an empty capsid and, therefore, may be classified under" exact="type II" post="DNA-packaging. However, the exact mechanism of the DNA packaging"/>
  <result pre="[91]. This mechanism begins with the DNA-binding domain binding the" exact="viral" post="DNA. Once the DNA is bound, the DNA-binding domain"/>
  <result pre="Once the DNA is bound, the DNA-binding domain moves the" exact="viral" post="DNA closer to the ATPase domain of the same"/>
  <result pre="DNA-binding domain in such a way that it pushes the" exact="viral" post="DNA into the capsid. When ADP and Pi are"/>
  <result pre="a connecter protein in the packaging motor rotating around the" exact="viral" post="DNA and, therefore, using this movement to screw the"/>
  <result pre="channel. Proteins directly involved in the propagation of the concatemeric" exact="viral" post="DNA into the capsid have a significant potential as"/>
  <result pre="just in the packaging motor, but in all of the" exact="viral" post="proteins. Since only a partial experimental structure of this"/>
  <result pre="but in all of the viral proteins. Since only a" exact="partial" post="experimental structure of this protein is available currently, we"/>
  <result pre="in this publication was supported by the National Institute of" exact="General" post="Medical Sciences of the National Institutes of Health under"/>
  <result pre="3.PenkertR.R.KalejtaR.F.Tegument protein control of latent herpesvirus establishment and animationHerpesviridae20112310.1186/2042-4280-2-321429246 4.ChisholmC.LopezL.Cutaneous" exact="infections" post="caused by herpesviridae: A reviewArch. Pathol. Lab. Med.20111351357136210.5858/arpa.2010-0156-RS21970493 5.GrindeB.Herpesviruses:"/>
  <result pre="A reviewArch. Pathol. Lab. Med.20111351357136210.5858/arpa.2010-0156-RS21970493 5.GrindeB.Herpesviruses: Latency and reactivation -" exact="viral" post="strategies and host responseJ. Oral. Microbiol.201352276610.3402/jom.v5i0.2276624167660 6.KottonC.N.Management of cytomegalovirus"/>
  <result pre="- viral strategies and host responseJ. Oral. Microbiol.201352276610.3402/jom.v5i0.2276624167660 6.KottonC.N.Management of" exact="cytomegalovirus infection" post="in solid organ transplantationNat. Rev. Nephrol.2010671172110.1038/nrneph.2010.14120978468 7.WhitleyR.J.HerpesvirusesMedical Microbiology4th ed.BaronS.University"/>
  <result pre="viral strategies and host responseJ. Oral. Microbiol.201352276610.3402/jom.v5i0.2276624167660 6.KottonC.N.Management of cytomegalovirus" exact="infection" post="in solid organ transplantationNat. Rev. Nephrol.2010671172110.1038/nrneph.2010.14120978468 7.WhitleyR.J.HerpesvirusesMedical Microbiology4th ed.BaronS.University"/>
  <result pre="7.WhitleyR.J.HerpesvirusesMedical Microbiology4th ed.BaronS.University of Texas Medical BranchGalveston, TX, USA1996 8.BoppanaS.B.FowlerK.B.BrittW.J.StagnoS.PassR.F.Symptomatic" exact="congenital" post="cytomegalovirus infection in infants born to mothers with preexisting"/>
  <result pre="Microbiology4th ed.BaronS.University of Texas Medical BranchGalveston, TX, USA1996 8.BoppanaS.B.FowlerK.B.BrittW.J.StagnoS.PassR.F.Symptomatic congenital" exact="cytomegalovirus infection" post="in infants born to mothers with preexisting immunity to"/>
  <result pre="ed.BaronS.University of Texas Medical BranchGalveston, TX, USA1996 8.BoppanaS.B.FowlerK.B.BrittW.J.StagnoS.PassR.F.Symptomatic congenital cytomegalovirus" exact="infection" post="in infants born to mothers with preexisting immunity to"/>
  <result pre="infants born to mothers with preexisting immunity to cytomegalovirusPediatrics1999104556010.1542/peds.104.1.5510390260 9.BoppanaS.B.PassR.F.BrittW.J.StagnoS.AlfordC.A.Symptomatic" exact="congenital" post="cytomegalovirus infection: Neonatal morbidity and mortalityPediatr. Infect. Dis. J.199211939910.1097/00006454-199202000-000071311066"/>
  <result pre="mothers with preexisting immunity to cytomegalovirusPediatrics1999104556010.1542/peds.104.1.5510390260 9.BoppanaS.B.PassR.F.BrittW.J.StagnoS.AlfordC.A.Symptomatic congenital cytomegalovirus infection:" exact="Neonatal" post="morbidity and mortalityPediatr. Infect. Dis. J.199211939910.1097/00006454-199202000-000071311066 10.CollO.BenoistG.VilleY.WeismanL.E.BotetF.AnceschiM.M.GreenoughA.GibbsR.S.Carbonell-EstranyX.GroupW.P.I.W.Guidelines on CMV"/>
  <result pre="Neonatal morbidity and mortalityPediatr. Infect. Dis. J.199211939910.1097/00006454-199202000-000071311066 10.CollO.BenoistG.VilleY.WeismanL.E.BotetF.AnceschiM.M.GreenoughA.GibbsR.S.Carbonell-EstranyX.GroupW.P.I.W.Guidelines on CMV" exact="congenital" post="infectionJ. Perinat. Med.20093743344510.1515/JPM.2009.12719673682 11.PeritzD.C.DuncanC.KurekK.Perez-AtaydeA.R.LehmannL.E.Visceral varicella zoster virus (VZV) after"/>
  <result pre="Dis. J.199211939910.1097/00006454-199202000-000071311066 10.CollO.BenoistG.VilleY.WeismanL.E.BotetF.AnceschiM.M.GreenoughA.GibbsR.S.Carbonell-EstranyX.GroupW.P.I.W.Guidelines on CMV congenital infectionJ. Perinat. Med.20093743344510.1515/JPM.2009.12719673682 11.PeritzD.C.DuncanC.KurekK.Perez-AtaydeA.R.LehmannL.E.Visceral" exact="varicella" post="zoster virus (VZV) after allogeneic hematopoietic stem cell transplant"/>
  <result pre="J.199211939910.1097/00006454-199202000-000071311066 10.CollO.BenoistG.VilleY.WeismanL.E.BotetF.AnceschiM.M.GreenoughA.GibbsR.S.Carbonell-EstranyX.GroupW.P.I.W.Guidelines on CMV congenital infectionJ. Perinat. Med.20093743344510.1515/JPM.2009.12719673682 11.PeritzD.C.DuncanC.KurekK.Perez-AtaydeA.R.LehmannL.E.Visceral varicella" exact="zoster" post="virus (VZV) after allogeneic hematopoietic stem cell transplant (HSCT)"/>
  <result pre="allogeneic hematopoietic stem cell transplant (HSCT) in pediatric patients with" exact="chronic" post="graft-versus-host disease (cGVHD)J. Pediatr. Hematol. Oncol.20083093193410.1097/MPH.0b013e31817e4b1419131784 12.BonnetM.GuinebretiereJ.M.KremmerE.GrunewaldV.BenhamouE.ContessoG.JoabI.Detection of Epstein-Barr"/>
  <result pre="stem cell transplant (HSCT) in pediatric patients with chronic graft-versus-host" exact="disease" post="(cGVHD)J. Pediatr. Hematol. Oncol.20083093193410.1097/MPH.0b013e31817e4b1419131784 12.BonnetM.GuinebretiereJ.M.KremmerE.GrunewaldV.BenhamouE.ContessoG.JoabI.Detection of Epstein-Barr virus in"/>
  <result pre="(cGVHD)J. Pediatr. Hematol. Oncol.20083093193410.1097/MPH.0b013e31817e4b1419131784 12.BonnetM.GuinebretiereJ.M.KremmerE.GrunewaldV.BenhamouE.ContessoG.JoabI.Detection of Epstein-Barr virus in invasive" exact="breast" post="cancersJ. Natl. Cancer Inst.1999911376138110.1093/jnci/91.16.137610451442 13.WongM.PaganoJ.S.SchillerJ.T.TevethiaS.S.Raab-TraubN.GruberJ.New associations of human papillomavirus,"/>
  <result pre="Oncol.20083093193410.1097/MPH.0b013e31817e4b1419131784 12.BonnetM.GuinebretiereJ.M.KremmerE.GrunewaldV.BenhamouE.ContessoG.JoabI.Detection of Epstein-Barr virus in invasive breast cancersJ. Natl." exact="Cancer" post="Inst.1999911376138110.1093/jnci/91.16.137610451442 13.WongM.PaganoJ.S.SchillerJ.T.TevethiaS.S.Raab-TraubN.GruberJ.New associations of human papillomavirus, Simian virus 40,"/>
  <result pre="Simian virus 40, and Epstein-Barr virus with human cancerJ. Natl." exact="Cancer" post="Inst.2002941832183610.1093/jnci/94.24.183212488476 14.SchulzT.F.The pleiotropic effects of Kaposi’s sarcoma herpesvirusJ. Pathol.200620818719810.1002/path.190416362980"/>
  <result pre="human cancerJ. Natl. Cancer Inst.2002941832183610.1093/jnci/94.24.183212488476 14.SchulzT.F.The pleiotropic effects of Kaposi’s" exact="sarcoma" post="herpesvirusJ. Pathol.200620818719810.1002/path.190416362980 15.SunilM.ReidE.LechowiczM.J.Update on HHV-8-Associated MalignanciesCurr. Infect. Dis. Rep.20101214715410.1007/s11908-010-0092-520461118"/>
  <result pre="herpesvirusJ. Pathol.200620818719810.1002/path.190416362980 15.SunilM.ReidE.LechowiczM.J.Update on HHV-8-Associated MalignanciesCurr. Infect. Dis. Rep.20101214715410.1007/s11908-010-0092-520461118 16.McGeochD.J.DalrympleM.A.DavisonA.J.DolanA.FrameM.C.McNabD.PerryL.J.ScottJ.E.TaylorP.The" exact="complete" post="DNA sequence of the long unique region in the"/>
  <result pre="sequence of the long unique region in the genome of" exact="herpes" post="simplex virus type 1J. Gen. Virol.1988691531157410.1099/0022-1317-69-7-15312839594 17.MacdonaldS.J.MostafaH.H.MorrisonL.A.DavidoD.J.Genome sequence of"/>
  <result pre="long unique region in the genome of herpes simplex virus" exact="type 1J." post="Gen. Virol.1988691531157410.1099/0022-1317-69-7-15312839594 17.MacdonaldS.J.MostafaH.H.MorrisonL.A.DavidoD.J.Genome sequence of herpes simplex virus 1"/>
  <result pre="herpes simplex virus type 1J. Gen. Virol.1988691531157410.1099/0022-1317-69-7-15312839594 17.MacdonaldS.J.MostafaH.H.MorrisonL.A.DavidoD.J.Genome sequence of" exact="herpes" post="simplex virus 1 strain KOSJ. Virol.2012866371637210.1128/JVI.00646-1222570244 18.MacdonaldS.J.MostafaH.H.MorrisonL.A.DavidoD.J.Genome sequence of"/>
  <result pre="herpes simplex virus 1 strain KOSJ. Virol.2012866371637210.1128/JVI.00646-1222570244 18.MacdonaldS.J.MostafaH.H.MorrisonL.A.DavidoD.J.Genome sequence of" exact="herpes" post="simplex virus 1 strain McKraeJ. Virol.2012869540954110.1128/JVI.01469-1222879612 19.DavisonA.J.Comparative analysis of"/>
  <result pre="and ImmunoprophylaxisCampadelli-FiumeA.A.MocarskiG.E.Cambridge University PressCambridge, UK2007 20.KaramitrosT.HarrisonI.PiorkowskaR.KatzourakisA.MagiorkinisG.MbisaJ.L.De novo assembly of human" exact="herpes" post="virus type 1 (HHV-1) genome, mining of non-canonical structures"/>
  <result pre="University PressCambridge, UK2007 20.KaramitrosT.HarrisonI.PiorkowskaR.KatzourakisA.MagiorkinisG.MbisaJ.L.De novo assembly of human herpes virus" exact="type 1" post="(HHV-1) genome, mining of non-canonical structures and detection of"/>
  <result pre="Opin. Infect. Dis.20132655156010.1097/QCO.000000000000001524152761 22.RazonableR.R.Antiviral drugs for viruses other than human" exact="immunodeficiency" post="virusMayo. Clin. Proc.2011861009102610.4065/mcp.2011.030921964179 23.GriffithsP.D.BoeckM.Antiviral therapy for human cytomegalovirusHuman Herpesviruses:"/>
  <result pre="drug resistance of human cytomegalovirusClin. Microbiol. Rev.20102368971210.1128/CMR.00009-1020930070 28.SchreiberA.HarterG.SchubertA.BunjesD.MertensT.MichelD.Antiviral treatment of" exact="cytomegalovirus infection" post="and resistant strainsExpert. Opin. Pharmacother.20091019120910.1517/1465656080267813819236193 29.YangL.YangQ.WangM.JiaR.ChenS.ZhuD.LiuM.WuY.ZhaoX.ZhangS.et al.Terminase large subunit"/>
  <result pre="resistance of human cytomegalovirusClin. Microbiol. Rev.20102368971210.1128/CMR.00009-1020930070 28.SchreiberA.HarterG.SchubertA.BunjesD.MertensT.MichelD.Antiviral treatment of cytomegalovirus" exact="infection" post="and resistant strainsExpert. Opin. Pharmacother.20091019120910.1517/1465656080267813819236193 29.YangL.YangQ.WangM.JiaR.ChenS.ZhuD.LiuM.WuY.ZhaoX.ZhangS.et al.Terminase large subunit"/>
  <result pre="cytomegalovirus replication through a specific antiviral mechanism that involves the" exact="viral" post="terminaseJ. Virol.201185108841089310.1128/JVI.05265-1121752907 32.MelendezD.P.RazonableR.R.Letermovir and inhibitors of the terminase complex:"/>
  <result pre="antiviral drugs against human cytomegalovirusInfect. Drug Resist.2015826927726345608 33.YangK.DangX.BainesJ.D.A domain of" exact="herpes" post="simplex virus pUL33 required to release monomeric viral genomes"/>
  <result pre="domain of herpes simplex virus pUL33 required to release monomeric" exact="viral" post="genomes from cleaved concatemeric DNAJ. Virol201791e00854-1710.1128/JVI.00854-1728747509 34.KroskyP.M.UnderwoodM.R.TurkS.R.FengK.W.JainR.K.PtakR.G.WestermanA.C.BironK.K.TownsendL.B.DrachJ.C.Resistance of human"/>
  <result pre="Virol.200579146601466710.1128/JVI.79.23.14660-14667.200516282466 41.ZhouB.YangK.WillsE.TangL.BainesJ.D.A mutation in the DNA polymerase accessory factor of" exact="herpes" post="simplex virus 1 restores viral DNA replication in the"/>
  <result pre="DNA polymerase accessory factor of herpes simplex virus 1 restores" exact="viral" post="DNA replication in the presence of raltegravirJ. Virol.201488111211112910.1128/JVI.01540-1425008933 42.GoldnerT.ZimmermannH.LischkaP.Phenotypic"/>
  <result pre="Chemother.2012561135113710.1128/AAC.05908-1122106211 45.Caruso BrownA.E.CohenM.N.TongS.BravermanR.S.RooneyJ.F.GillerR.LevinM.J.Pharmacokinetics and safety of intravenous cidofovir for life-threatening" exact="viral" post="infections in pediatric hematopoietic stem cell transplant recipientsAntimicrob. Agents"/>
  <result pre="45.Caruso BrownA.E.CohenM.N.TongS.BravermanR.S.RooneyJ.F.GillerR.LevinM.J.Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral" exact="infections" post="in pediatric hematopoietic stem cell transplant recipientsAntimicrob. Agents Chemother.2015593718372510.1128/AAC.04348-1425733509"/>
  <result pre="hematopoietic stem cell transplant recipientsAntimicrob. Agents Chemother.2015593718372510.1128/AAC.04348-1425733509 46.ChenK.ChengM.P.HammondS.P.EinseleH.MartyF.M.Antiviral prophylaxis for" exact="cytomegalovirus infection" post="in allogeneic hematopoietic cell transplantationBlood Adv.201822159217510.1182/bloodadvances.201801649330154125 47.ClarkK.Karsch-MizrachiI.LipmanD.J.OstellJ.SayersE.W.GenBankNucleic Acids Res.201644677210.1093/nar/gkv127626590407"/>
  <result pre="stem cell transplant recipientsAntimicrob. Agents Chemother.2015593718372510.1128/AAC.04348-1425733509 46.ChenK.ChengM.P.HammondS.P.EinseleH.MartyF.M.Antiviral prophylaxis for cytomegalovirus" exact="infection" post="in allogeneic hematopoietic cell transplantationBlood Adv.201822159217510.1182/bloodadvances.201801649330154125 47.ClarkK.Karsch-MizrachiI.LipmanD.J.OstellJ.SayersE.W.GenBankNucleic Acids Res.201644677210.1093/nar/gkv127626590407"/>
  <result pre="Current status, taxonomic expansion, and functional annotationNucleic Acids Res.20164473374510.1093/nar/gkv1189 56.EdgarR.C.MUSCLE:" exact="Multiple" post="sequence alignment with high accuracy and high throughputNucleic Acids"/>
  <result pre="https://inkscape.org/.(accessed on 9 October 2019) 62.Selvarajan SigamaniS.ZhaoH.KamauY.N.BainesJ.D.TangL.The structure of the" exact="herpes" post="simplex virus DNA-packaging terminase pUL15 nuclease domain suggests an"/>
  <result pre="evolutionary lineage among eukaryotic and prokaryotic virusesJ. Virol.2013877140714810.1128/JVI.00311-1323596306 63.BermanH.M.BattistuzT.BhatT.N.BluhmW.F.BourneP.E.BurkhardtK.FengZ.GillilandG.L.IypeL.JainS.et al.The" exact="Protein" post="Data BankActa Crystallogr. D Biol. Crystallogr.20025889990710.1107/S090744490200345112037327 64.SunS.KondabagilK.GentzP.M.RossmannM.G.RaoV.B.The structure of"/>
  <result pre="sequences and structuresBioinformatics2012282072207310.1093/bioinformatics/bts30222618536 69.WebbB.SaliA.Comparative protein structure modeling using MODELLERCurr. Protoc." exact="Protein" post="Sci.2014475610.1002/0471250953.bi0506s4725199792 70.BrylinskiM.FeinsteinW.P.eFindSite: Improved prediction of ligand binding sites in"/>
  <result pre="ligand docking and binding affinity predictionJ. Chem. Inf. Model.2013533097311210.1021/ci400510e24171431 73.LaskowskiR.A.SwindellsM.B.LigPlot+:" exact="Multiple" post="ligand-protein interaction diagrams for drug discoveryJ. Chem. Inf. Model.2011512778278610.1021/ci200227u21919503"/>
  <result pre="Switzerland2016 83.JohnstonC.GottliebS.L.WaldA.Status of vaccine research and development of vaccines for" exact="herpes" post="simplex virusVaccine2016342948295210.1016/j.vaccine.2015.12.07626973067 84.DeshpandeS.P.KumaraguruU.RouseB.T.Why do we lack an effective vaccine"/>
  <result pre="simplex virusVaccine2016342948295210.1016/j.vaccine.2015.12.07626973067 84.DeshpandeS.P.KumaraguruU.RouseB.T.Why do we lack an effective vaccine against" exact="herpes" post="simplex virus infections?Microbes. Infect.2000297397810.1016/S1286-4579(00)00339-710962281 85.LookerK.J.MagaretA.S.TurnerK.M.VickermanP.GottliebS.L.NewmanL.M.Global estimates of prevalent and"/>
  <result pre="simplex virus infections?Microbes. Infect.2000297397810.1016/S1286-4579(00)00339-710962281 85.LookerK.J.MagaretA.S.TurnerK.M.VickermanP.GottliebS.L.NewmanL.M.Global estimates of prevalent and incident" exact="herpes" post="simplex virus type 2 infections in 2012PLoS ONE201510e11498910.1371/journal.pone.011498925608026 86.World"/>
  <result pre="Infect.2000297397810.1016/S1286-4579(00)00339-710962281 85.LookerK.J.MagaretA.S.TurnerK.M.VickermanP.GottliebS.L.NewmanL.M.Global estimates of prevalent and incident herpes simplex virus" exact="type 2" post="infections in 2012PLoS ONE201510e11498910.1371/journal.pone.011498925608026 86.World Health OrganizationAvailable online: https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus(accessed"/>
  <result pre="estimates of prevalent and incident herpes simplex virus type 2" exact="infections" post="in 2012PLoS ONE201510e11498910.1371/journal.pone.011498925608026 86.World Health OrganizationAvailable online: https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus(accessed on"/>
  <result pre="on 9 October 2019) 87.McQuillanG.Kruszon-MoranD.FlaggE.W.Paulose-RamR.In Prevalence of Herpes Simplex Virus" exact="Type 1" post="and Type 2 in Persons Aged 14-49: USA, 2015-2016NCHS"/>
  <result pre="2019) 87.McQuillanG.Kruszon-MoranD.FlaggE.W.Paulose-RamR.In Prevalence of Herpes Simplex Virus Type 1 and" exact="Type 2" post="in Persons Aged 14-49: USA, 2015-2016NCHS Data Brief.201830418 88.PrzechA.J.YuD.WellerS.K.Point"/>
  <result pre="2015-2016NCHS Data Brief.201830418 88.PrzechA.J.YuD.WellerS.K.Point mutations in exon I of the" exact="herpes" post="simplex virus putative terminase subunit, UL15, indicate that the"/>
  <result pre="in proteinsBMC Bioinformatics2018199110.1186/s12859-018-2109-229523085 91.PiF.ZhaoZ.ChelikaniV.YoderK.KvaratskheliaM.GuoP.Development of Potent Antiviral Drugs Inspired by" exact="Viral" post="Hexameric DNA-Packaging Motors with Revolving MechanismJ. Virol.2016908036804610.1128/JVI.00508-1627356896 92.SunS.RaoV.B.RossmannM.G.Genome packaging"/>
  <result pre="virusesCurr. Opin. Struct. Biol.20102011412010.1016/j.sbi.2009.12.00620060706 93.WatersJ.T.KimH.D.GumbartJ.C.LuX.J.HarveyS.C.DNA Scrunching in the Packaging of" exact="Viral" post="GenomesJ. Phys. Chem. B.20161206200620710.1021/acs.jpcb.6b0214927214211 Figure 1 Number of papers"/>
  <result pre="and computational). Figure 2 Posterior distributions of relative substitution rates." exact="Protein" post="products of HHV-1 involved in the packaging of DNA"/>
  <result pre="Sequences are labeled by virus abbreviations. Each node shows the" exact="posterior" post="probability value from a Bayesian analysis followed by the"/>
  <result pre="59.0% Human Gammaherpesvirus 4 HHV-4 YP 401690.1 32.2% Human Betaherpesvirus" exact="Type 5" post="HHV-5 YP_081537.1 36.0% Human Betaherpesvirus 6B HHV-6B NP_050241.1 34.5%"/>
  <result pre="FHV-1 YP_003331564.1 64.3% Fruit bat Alphaherpesvirus 1 FBAHV-1 YP_009042077.1 82.6%" exact="Bovine" post="Alphaherpesvirus 1 BHV-1 NP 045342.1 60.4% Bovine Gammaherpesvirus 4"/>
  <result pre="FBAHV-1 YP_009042077.1 82.6% Bovine Alphaherpesvirus 1 BHV-1 NP 045342.1 60.4%" exact="Bovine" post="Gammaherpesvirus 4 BHV-4 NP 076521.1 31.3% Bovine Alphaherpesvirus 5"/>
  <result pre="NP 045342.1 60.4% Bovine Gammaherpesvirus 4 BHV-4 NP 076521.1 31.3%" exact="Bovine" post="Alphaherpesvirus 5 BHV-5 YP 003662508.1 60.6% Bovine Gammaherpesvirus 6"/>
  <result pre="NP 076521.1 31.3% Bovine Alphaherpesvirus 5 BHV-5 YP 003662508.1 60.6%" exact="Bovine" post="Gammaherpesvirus 6 BHV-6 YP 009042007.1 31.0% Gallid Alphaherpesvirus 2"/>
 </snippets>
</snippetsTree>
